I will say this, all of the monoclonal antibody therapies are biologics under EUA. They are neutralizing antibodies that target a part of the SARS-CoV-2 spike protein. If this is of concern, all mAbs are developed using human fetal cell lines for testing. REGEN-COV used immortalized HEK cells in its original research. Theoretically mAbs are a short term stop gap in disease progression to help until natural antibodies can be made by the body that are long lasting and have the ability to tackle variants.

The two antibodies used in REGEN-COV are derived from Regeneron’s trademarked humanized mice, which are genetically modified to have a human immune system, and B cells from the convalescent patients who have recovered from the COVID-19. REGEN-COV is made with synthetic proteins that are foreign to the body. It is hard to say what they gave these mice to generate antibodies since there are no known isolates of the virus.

Sotrovimab is a recombinant human IGg mAb that was tweaked to have an extended half life. It was developed using antibodies collected in 2003 from the first cases of SARS. The particular epitope targeted on the spike protein is believed not to be prone to mutation, thus allowing it to be effective against subsequent variants.

Monoclonal antibody therapy's effects are short lived and they can have side effects - just the same as any other biologic therapy. We do not know what the long term effects are of using either the synthetic proteins or the recombinant cellular derived genetic brew - pick your poison. The best line of attack against not just SARS-CoV-2, but other viruses, is still Ivermectin and HCQ along with certain supplements. We pretty much know what we are getting using these drugs and supplements as far as safety and efficacy. Remember, all the drugs coming out for Covid are made and distributed by the same cast of characters. Prevention and early treatment of illness is the key to not being hospitalized or needing experimental mAbs therapy.

I will say this, all of the monoclonal antibody therapies are biologics under EUA. They are neutralizing antibodies that target a part of the SARS-CoV-2 spike protein. If this is of concern, all mAbs are developed using human fetal cell lines for testing. REGEN-COV used immortalized HEK cells in its original research. Theoretically mAbs are a short term stop gap in disease progression to help until natural antibodies can be made by the body that are long lasting and have the ability to tackle variants.

The two antibodies used in REGEN-COV are derived from Regeneron’s trademarked humanized mice, which are genetically modified to have a human immune system, and B cells from the convalescent patients who have recovered from the COVID-19. REGEN-COV is made with synthetic proteins that are foreign to the body. It is hard to say what they gave these mice to generate antibodies since there are no known isolates of the virus.

Sotrovimab is a recombinant human IGg mAb that was tweaked to have an extended half life. It was developed using antibodies collected in 2003 from the first cases of SARS. The particular epitope targeted on the spike protein is believed not to be prone to mutation, thus allowing it to be effective against subsequent variants.

Monoclonal antibody therapy's effects are short lived and they can have side effects - just the same as any other biologic therapy. We do not know what the long term effects are of using either the synthetic proteins or the recombinant cellular derived genetic brew - pick your poison. The best line of attack against not just SARS-CoV-2, but other viruses, is still Ivermectin and HCQ along with certain supplements. We pretty much know what we are getting using these drugs and supplements as far as safety and efficacy. Remember, all the drugs coming out for Covid are made and distributed by the same cast of characters.